Safety Study to Assess IV Zanamivir for Treatment of Influenza Infection in Patients Who Are in Hospital

PHASE2CompletedINTERVENTIONAL
Enrollment

202

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Influenza, Human
Interventions
DRUG

zanamivir aqueous solution

Zanamivir aqueous solution 10mg/mL is a clear, colorless, single use, sterile non-preserved preparation containing 10mg of zanamivir in each milliliter, and made isotonic with sodium chloride. It is presented in 20mL clear glass vials closed with rubber stoppers. Each vial contains 200mg of zanamivir.

Trial Locations (110)

1055

GSK Investigational Site, Middelburg

2606

GSK Investigational Site, Garran

3084

GSK Investigational Site, Heidelberg

4029

GSK Investigational Site, Herston

4032

GSK Investigational Site, Chermside

5000

GSK Investigational Site, Adelaide

5021

GSK Investigational Site, Bergen

5043

GSK Investigational Site, Bedford Park

6000

GSK Investigational Site, Perth

6008

GSK Investigational Site, Subiaco

6850

GSK Investigational Site, Worcester

7030

GSK Investigational Site, Trondheim

7500

GSK Investigational Site, Panorama

7505

GSK Investigational Site, Tygerberg

7530

GSK Investigational Site, Bellville

7700

GSK Investigational Site, Rondebosch

7925

GSK Investigational Site, Observatory

10330

GSK Investigational Site, Bangkok

10700

GSK Investigational Site, Bangkok

11040

GSK Investigational Site, New Hyde Park

15224

GSK Investigational Site, Pittsburgh

19102

GSK Investigational Site, Philadelphia

20007

GSK Investigational Site, Washington D.C.

20010

GSK Investigational Site, Washington D.C.

23249

GSK Investigational Site, Richmond

27514

GSK Investigational Site, Chapel Hill

28007

GSK Investigational Site, Madrid

28034

GSK Investigational Site, Madrid

28041

GSK Investigational Site, Madrid

28046

GSK Investigational Site, Madrid

28203

GSK Investigational Site, Charlotte

28905

GSK Investigational Site, Getafe/Madrid

28935

GSK Investigational Site, (Móstoles) Madrid

30029

GSK Investigational Site, Nîmes

30033

GSK Investigational Site, Decatur

30322

GSK Investigational Site, Atlanta

32608

GSK Investigational Site, Gainesville

33606

GSK Investigational Site, Tampa

35233

GSK Investigational Site, Birmingham

37044

GSK Investigational Site, Tours

38043

GSK Investigational Site, Grenoble

38103

GSK Investigational Site, Memphis

38105

GSK Investigational Site, Memphis

40202

GSK Investigational Site, Louisville

43205

GSK Investigational Site, Columbus

43606

GSK Investigational Site, Toledo

44106

GSK Investigational Site, Cleveland

45067

GSK Investigational Site, Orléans

46202

GSK Investigational Site, Indianapolis

53201

GSK Investigational Site, Milwaukee

54035

GSK Investigational Site, Nancy

55102

GSK Investigational Site, Saint Paul

59701

GSK Investigational Site, Butte

63110

GSK Investigational Site, St Louis

64108

GSK Investigational Site, Kansas City

66604

GSK Investigational Site, Topeka

69677

GSK Investigational Site, Bron

70112

GSK Investigational Site, New Orleans

72202

GSK Investigational Site, Little Rock

75018

GSK Investigational Site, Paris

75231

GSK Investigational Site, Dallas

75235

GSK Investigational Site, Dallas

75679

GSK Investigational Site, Paris

76104

GSK Investigational Site, Fort Worth

77030

GSK Investigational Site, Houston

84113

GSK Investigational Site, Salt Lake City

85023

GSK Investigational Site, Phoenix

87042

GSK Investigational Site, Limoges

92123

GSK Investigational Site, San Diego

97239

GSK Investigational Site, Portland

214006

GSK Investigational Site, Smolensk

620102

GSK Investigational Site, Yekaterinburg

06902

GSK Investigational Site, Stamford

02115-5724

GSK Investigational Site, Boston

02115

GSK Investigational Site, Boston

08103

GSK Investigational Site, Camden

21941-590

GSK Investigational Site, Rio de Janeiro

01308060

GSK Investigational Site, São Paulo

R3E 0J9

GSK Investigational Site, Winnipeg

B3K 6R8

GSK Investigational Site, Halifax

M5G 1X5

GSK Investigational Site, Toronto

G7H 5H6

GSK Investigational Site, Chicoutimi

H1T 2M4

GSK Investigational Site, Montreal

H3T 1C5

GSK Investigational Site, Montreal

G1V 4G2

GSK Investigational Site, Québec

06200

GSK Investigational Site, Nice

Unknown

GSK Investigational Site, Shatin

830-8543

GSK Investigational Site, Fukuoka

062-0931

GSK Investigational Site, Hokkaido

247-8533

GSK Investigational Site, Kanagawa

534-0021

GSK Investigational Site, Osaka

596-8522

GSK Investigational Site, Osaka

400-8506

GSK Investigational Site, Yamanashi

08916

GSK Investigational Site, Badalona

08003

GSK Investigational Site, Barcelona

08035

GSK Investigational Site, Barcelona

08036

GSK Investigational Site, Barcelona

08907

GSK Investigational Site, L'Hospitalet de Llobregat

G11 6NT

GSK Investigational Site, Glasgow

L7 8XP

GSK Investigational Site, Liverpool

EH54 6PP

GSK Investigational Site, Livingston

BS2 8AE

GSK Investigational Site, Bristol

BS2 8HW

GSK Investigational Site, Bristol

CF14 4XW

GSK Investigational Site, Cardiff

LS1 3EX

GSK Investigational Site, Leeds

LE1 5WW

GSK Investigational Site, Leicester

LE3 9QP

GSK Investigational Site, Leicester

NW1 2BU

GSK Investigational Site, London

OX3 9DU

GSK Investigational Site, Oxford

SO16 6YD

GSK Investigational Site, Southampton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01014988 - Safety Study to Assess IV Zanamivir for Treatment of Influenza Infection in Patients Who Are in Hospital | Biotech Hunter | Biotech Hunter